DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $99.06.

Several research firms have recently commented on DXCM. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Wells Fargo & Company lifted their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Citigroup upped their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC boosted its stake in DexCom by 5.7% during the 3rd quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock worth $759,000 after purchasing an additional 608 shares during the last quarter. International Assets Investment Management LLC acquired a new position in DexCom during the third quarter worth about $930,000. Hennion & Walsh Asset Management Inc. boosted its position in DexCom by 15.1% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock worth $296,000 after acquiring an additional 579 shares during the last quarter. State of Alaska Department of Revenue grew its stake in DexCom by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock valued at $3,110,000 after acquiring an additional 3,155 shares in the last quarter. Finally, abrdn plc raised its holdings in DexCom by 28.4% in the 3rd quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock valued at $25,842,000 after acquiring an additional 85,174 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 1.8 %

Shares of NASDAQ:DXCM opened at $89.91 on Thursday. The business’s 50-day moving average is $84.29 and its 200 day moving average is $76.47. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a market capitalization of $35.13 billion, a P/E ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.